Biomarkers of Conversion Risk and Treatment Response in Early-Stage Schizophrenia

NCT03323437 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

26

Enrollment

OTHER

Sponsor class

Conditions

Schizophrenia Spectrum and Other Psychotic Disorders

Interventions

DRUG: Risperidone

Sponsor

Weill Medical College of Cornell University

Collaborators

[object Object]
[object Object]
[object Object]